These findings aligned with prior studies [23, 31–34] documenting the overexpression of DDR1 and its role in therapy resistance across multiple malignancies like colorectal, breast and lung cancer, indicating that there might be a conserved mechanism across malignancies and DDR1 had the potential to be a cancer target. The gene discussed is DDR1; the disease is lung carcinoma.